Phase I study of twice weekly 5-azacytidine (NSC-102816).
D001374:Azacitidine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001772:Blood Cell Count; D001792:Blood Platelets; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006098:Granulocytes; D006452:Hemoglobinometry; D006801:Humans; D007677:Kidney Function Tests; D008111:Liver Function Tests; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy*; D013997:Time Factors
D001374:Azacitidine